Genetech posts
FeedPosted Jan 14th 2009 11:05AM by Jamie Dlugosch (RSS feed)
Filed under: Deals, Employees, Genentech Inc (DNA)

After the initial rebuff of Swiss-based pharmaceutical giant Roche's offer to acquire the 44% of
Genentech (NYSE:
DNA) stock Roche does not currently own, DNA is coyly encouraging the completion of a deal at a higher price.
Genentech is among the leading biotech companies in the world. It is engaged in the discovery, development, manufacturing and commercialization of pharmaceutical products intended for treatment of previously untreatable illnesses.
In 1990, Roche acquired a 56% stake in the company. Since that time, the relationship between the two companies has been a model for similarly structured combinations.
Roche's offer of $89 per share for DNA was characterized by DNA as significantly undervaluing the company.
But this was hardly a "hit the road, Jack" response. DNA's board of directors has been encouraging the two sides to continue discussions, and recent comments suggest that the deal could come together soon.
Continue reading Don't sell your Genentech (DNA) stock just yet
Posted Mar 14th 2008 6:10PM by Jon Ogg (RSS feed)
Filed under: After the Bell, Major Movement, Bad News, Industry, Boeing Co (BA), duPont(E.I.)deNemours (DD), , Genentech Inc (DNA), S and P 500, DJIA, , NASDAQ
It was looking like we were about to have a good day at about 8:35 EST this morning after seeing flat CPI. But the day ended up long enough and bad that it feels like that CPI report came out a week ago because it was such a long day.
But today was all about Bear Stearns (NYSE: BSC), and you've already heard the news. If you have ever wondered what a run on the bank looks like and what a major institution on verge of implosion looks like, you just saw it today. Bear Stearns closed down over 45% to $30.85 on over 185 million shares. Free marketeers don't want a bailout.
It's bad enough out there that even someone out of the National Bureau of Economic Research is worried about a severe recession. If you want any good news on the day, it would be that the market didn't close on lows and it wasn't widespread panic falling out into every sector.
- DJIA 11,951.09 (-194.65; -1.60%)
- S&P500 1,288.14 (-27.34; -2.08%)
- NASDAQ 2,212.49 (-51.12; -2.26%)
- 10YR-TBond 3.4210% (-0.113%)
- The VIX closed at 31.16, up 3.87
- List of 52-week lows was a monster long list.
Continue reading Closing Bell: The good news was the closing bell
Posted Oct 20th 2007 12:40PM by Trey Thoelcke (RSS feed)
Filed under: Earnings Reports, Google (GOOG), Microsoft (MSFT), Yahoo! (YHOO), eBay (EBAY), Pfizer (PFE), Coca-Cola (KO), Intel (INTC), Motorola (MOT), McDonald's (MCD), International Business Machines (IBM), Nokia Corp. (NOK), Citigroup Inc. (C), Johnson and Johnson (JNJ), JPMorgan Chase (JPM), Advanced Micro Dev (AMD), Altria Group (MO), Bank of America (BAC), Boston Scientific (BSX), Hershey Co (HSY), Domino's Pizza (DPZ), Gannett Co (GCI), Mattel, Inc (MAT), Southwest Airlines (LUV), , , Harley-Davidson (HOG), United Technologies (UTX)
Another earnings season crunch is under way, and here are a some highlights of this past week's earnings coverage here at BloggingStocks:
Continue reading Earnings highlights: Tech stocks strong, financials weak
Posted Oct 16th 2007 12:11PM by Michael Fowlkes (RSS feed)
Filed under: Earnings Reports, Good news, Genentech Inc (DNA)

Usually when a company is able to beat analyst estimates for earnings the stock gets rewarded on Wall Street, but that is not the case today for pharmaceutical giant
Genentech Inc. (NYSE:
DNA). The company reported its
third quarter numbers last night, beating estimates by a penny, but the stock is being sold off by traders today, dropping 1.9% in early morning to$75.94 down $1.56.
Analysts had been expecting to see the company show earnings of 72 cents a share, and the actual results came in at 73 cents a share for the quarter. This past quarter the company was able to experience a 22 percent earnings jump, so why is the stock lower today?
The main reason why analysts are are beating up the stock today is concern over the company's ability to maintain its current momentum. Analysts are fearing that the company is not going to be able to continue to shine in the light of increased competition and a saturated market place.
Continue reading Genentech (DNA) beats estimates, but concerns linger on Wall Street